9 Meters Biopharma, Inc.

NasdaqCM:NMTR Stock Report

Mkt Cap: US$27.5m

We’ve recently updated our valuation analysis.

9 Meters Biopharma Valuation

Is NMTR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NMTR?

Other financial metrics that can be useful for relative valuation.

NMTR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does NMTR's PB Ratio compare to its peers?

The above table shows the PB ratio for NMTR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average6.4x
NTRB Nutriband
2.9x81.1%US$28.0m
PXMD PaxMedica
12xn/aUS$28.6m
ADMP Adamis Pharmaceuticals
10.3xn/aUS$29.4m
ZYNE Zynerba Pharmaceuticals
0.6x59.2%US$29.8m
NMTR 9 Meters Biopharma
2x47.5%US$27.5m

Price-To-Book vs Peers: NMTR is good value based on its Price-To-Book Ratio (2x) compared to the peer average (6.4x).


Price to Earnings Ratio vs Industry

How does NMTR's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.5%
n/an/an/a

Price-To-Book vs Industry: NMTR is expensive based on its Price-To-Book Ratio (2x) compared to the US Pharmaceuticals industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is NMTR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NMTR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NMTR's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of NMTR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NMTR ($2.12) is trading below our estimate of fair value ($259.08)

Significantly Below Fair Value: NMTR is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NMTR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.12
US$39.20
+1,747.3%
52.1%US$74.00US$10.00n/a5
Jan ’24US$1.26
US$39.20
+3,011.1%
52.1%US$74.00US$10.00n/a5
Dec ’23US$1.71
US$39.20
+2,192.4%
52.1%US$74.00US$10.00n/a5
Nov ’23US$2.53
US$66.80
+2,540.3%
29.7%US$100.00US$40.00n/a5
Oct ’23US$4.30
US$68.00
+1,481.4%
30.0%US$100.00US$40.00n/a5
Sep ’23US$5.04
US$64.00
+1,170.8%
23.4%US$80.00US$40.00n/a5
Aug ’23US$4.30
US$64.00
+1,388.4%
23.4%US$80.00US$40.00n/a5
Jul ’23US$4.50
US$64.00
+1,322.9%
23.4%US$80.00US$40.00n/a5
Jun ’23US$8.89
US$86.67
+874.7%
31.7%US$120.00US$40.00n/a6
May ’23US$8.36
US$86.67
+937.2%
31.7%US$120.00US$40.00n/a6
Apr ’23US$11.76
US$88.57
+653.0%
29.2%US$120.00US$40.00n/a7
Mar ’23US$11.43
US$88.57
+674.9%
29.2%US$120.00US$40.00n/a7
Feb ’23US$15.02
US$86.67
+476.9%
21.8%US$100.00US$60.00n/a6
Jan ’23US$19.57
US$92.00
+370.0%
17.4%US$100.00US$60.00US$1.265
Dec ’22US$20.00
US$96.67
+383.3%
18.6%US$120.00US$60.00US$1.716
Nov ’22US$25.60
US$98.33
+284.1%
18.9%US$120.00US$60.00US$2.536
Oct ’22US$25.80
US$98.33
+281.1%
18.9%US$120.00US$60.00US$4.306
Sep ’22US$25.80
US$98.00
+279.8%
20.8%US$120.00US$60.00US$5.045
Aug ’22US$21.60
US$91.67
+324.4%
25.5%US$120.00US$60.00US$4.306
Jul ’22US$22.20
US$90.00
+305.4%
28.1%US$120.00US$60.00US$4.505
Jun ’22US$25.40
US$97.50
+283.9%
23.4%US$120.00US$60.00US$8.894
May ’22US$24.40
US$100.00
+309.8%
24.5%US$120.00US$60.00US$8.364
Apr ’22US$24.20
US$100.00
+313.2%
24.5%US$120.00US$60.00US$11.764
Mar ’22US$34.80
US$85.00
+144.3%
30.6%US$120.00US$60.00US$11.434
Feb ’22US$30.00
US$85.00
+183.3%
30.6%US$120.00US$60.00US$15.024
Jan ’22US$17.18
US$80.00
+365.7%
25.0%US$100.00US$60.00US$19.574

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies